Workflow
Innovation Medical(002173)
icon
Search documents
华商创新医疗混合A:2025年上半年利润523.61万元 净值增长率17.87%
Sou Hu Cai Jing· 2025-09-05 09:40
Core Viewpoint - The AI Fund Huashang Innovation Medical Mixed A (017418) reported a profit of 5.2361 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.1359 yuan, and a net value growth rate of 17.87% during the reporting period [2] Group 1: Fund Performance - As of September 3, 2025, the fund's unit net value was 1.121 yuan, with a recent three-month net value growth rate of 25.16%, ranking 65 out of 138 in its category [5] - The fund's six-month net value growth rate was 27.59%, ranking 103 out of 138, while the one-year growth rate was 50.85%, ranking 85 out of 136 [5] - The fund's maximum drawdown since inception was 29.03%, with the largest quarterly drawdown occurring in Q1 2024 at 16.93% [26] Group 2: Fund Holdings and Valuation - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 16.88 times, significantly lower than the category average of 120.96 times [9] - The weighted average price-to-book (P/B) ratio was about 1.09 times, compared to the category average of 4.07 times, and the weighted average price-to-sales (P/S) ratio was approximately 0.99 times, against a category average of 6.52 times [9] - The fund's stock holdings showed a weighted revenue growth rate of 0.04% and a weighted net profit growth rate of 0.19% for the first half of 2025 [14] Group 3: Fund Management and Strategy - The fund manager, Peng Xinyang, oversees three funds, all of which have achieved positive returns over the past year, with the highest being Huashang Industrial Upgrade Mixed Fund at 66.97% [2] - The fund management anticipates that the global collaboration trend in innovative drugs will continue, benefiting the CXO industry from sustained R&D investments [2] - The report highlights the potential for innovative medical devices and the commercialization of medical AI to become new leading themes in the pharmaceutical industry [2] Group 4: Fund Structure and Investor Composition - As of June 30, 2025, the fund had a total of 369 holders, with a total of 37.1517 million shares held [33] - Institutional investors held 53.83% of the shares, while individual investors accounted for 46.17% [33] - The fund's average stock position since inception was 79.64%, with a peak of 90.68% in the first half of 2024 [29]
创新医疗龙虎榜数据(9月5日)
创新医疗今日下跌7.16%,全天换手率26.01%,成交额24.78亿元,振幅8.49%。龙虎榜数据显示,机构 净卖出1.71亿元,营业部席位合计净买入5037.54万元。 深交所公开信息显示,当日该股因日跌幅偏离值达-10.35%上榜,机构专用席位净卖出1.71亿元。 资金流向方面,今日该股主力资金净流出2.37亿元,其中,特大单净流出1.32亿元,大单资金净流出 1.05亿元。近5日主力资金净流出3230.67万元。(数据宝) 创新医疗9月5日交易公开信息 | 买/ | 会员营业部名称 | 买入金额(万 | 卖出金额(万 | | --- | --- | --- | --- | | 卖 | | 元) | 元) | | 买一 | 方正证券股份有限公司深圳翔鸽路证券营业部 | 6576.18 | 5233.28 | | 买二 | 国信证券股份有限公司浙江互联网分公司 | 3194.34 | 1826.62 | | 买三 | 东方财富证券股份有限公司拉萨金融城南环路证券营业 部 | 3005.88 | 2328.16 | | 买四 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | 2974.73 | 20 ...
创新医疗今日跌7.16%,有4家机构专用席位净卖出1.71亿元
Xin Lang Cai Jing· 2025-09-05 08:26
创新医疗今日跌7.16%,成交额24.78亿元,换手率26.01%,盘后龙虎榜数据显示,有4家机构专用席位 净卖出1.71亿元。 ...
江苏省1款第三类创新医疗器械获批上市
Yang Zi Wan Bao Wang· 2025-09-05 06:29
近期,苏州杰成医疗科技有限公司的"经导管主动脉瓣膜系统"第三类创新医疗(002173)器械通过国家 药监局审查,获批上市。 该产品为经股动脉入路,具有活动式定位件夹持原生主动脉瓣叶,可调弯输送系统适配横位心等复杂解 剖结构。适用于经心脏团队结合评分系统评估后认为患有有症状的、重度主动脉瓣膜关闭不全(重度主 动脉瓣反流),或同时合并主动脉瓣狭窄,不适合进行常规外科手术置换瓣膜、年龄大于等于70岁的患 者。产品由经导管生物瓣膜和经导管输送系统组成,通过微创介入技术,无需开胸手术即可完成瓣膜置 换,显著降低了手术风险,为高龄、无法耐受传统外科手术的患者提供了全新的治疗选择。 苏州杰成医疗科技有限公司"经导管主动脉瓣膜系统" 江苏省药监局深入贯彻落实国家创新驱动发展战略,持续深化审评审批制度改革,紧密围绕国家药监局 关于审评重心前移的工作部署,针对第三类创新医疗器械研发周期长、审评要求高等现实难题,不断优 化创新服务环境,完善审评前置机制。聚焦核心技术突破和"卡脖子"技术攻关,省药监局坚持以临床价 值为导向,强化医疗器械源头创新,围绕"前端帮扶、全程提速"的工作思路,通过深化审批改革、加强 技术支撑、优化产业生态等措 ...
脑机接口概念股盘初走低,创新医疗跌停
Mei Ri Jing Ji Xin Wen· 2025-09-05 01:44
Group 1 - Brain-computer interface concept stocks experienced a decline at the beginning of trading on September 5, with Innovation Medical hitting the daily limit down [1] - Rock Mountain Technology fell over 7%, while other companies such as Aipeng Medical, Sanbo Brain Science, and Jihua Group also saw significant drops [1]
东方创新医疗股票A:2025年上半年利润197.06万元 净值增长率12.88%
Sou Hu Cai Jing· 2025-09-04 15:51
Core Viewpoint - The AI Fund Oriental Innovation Medical Stock A (018045) reported a profit of 1.9706 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.109 yuan. The fund's net value growth rate was 12.88%, and the fund size reached 16.5886 million yuan by the end of the reporting period [2]. Fund Performance - As of September 3, 2025, the fund's net value growth rates were 32.62% over the past three months, 41.95% over the past six months, and 64.68% over the past year, ranking 13th, 27th, and 22nd respectively among comparable funds [5]. - The fund's maximum drawdown since inception was 28.85%, with the largest quarterly drawdown occurring in Q1 2024 at 23.3% [28]. Investment Strategy - The fund employs a combination of top-down industry analysis and bottom-up stock selection, focusing on innovative industry chains, pharmacies, consumer healthcare, and equipment upgrades while avoiding sectors in decline [2]. Fund Holdings and Valuation - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately -307.54, compared to the industry average of -135.64. The weighted average price-to-book (P/B) ratio was about 5, while the industry average was 4.24 [10]. - The fund's weighted average revenue growth rate for the first half of 2025 was 0.01%, and the weighted average net profit growth rate was 3.06% [16]. Fund Composition - As of June 30, 2025, the fund had a total of 642 holders, with individual investors holding 100% of the shares. The top ten holdings included companies such as Yuyuan Pharmaceutical, Maiwei Biotechnology, and Heng Rui Medicine [34][40]. - The fund's average stock position since inception was 73.6%, with a peak of 91.98% at the end of the first half of 2025 [31].
国投瑞银创新医疗混合A:2025年上半年利润945.16万元 净值增长率20.2%
Sou Hu Cai Jing· 2025-09-04 09:43
Core Viewpoint - The AI Fund Guotou UBS Innovative Medical Mixed A (005520) reported a profit of 9.4516 million yuan for the first half of 2025, with a net value growth rate of 20.2% and a fund size of 55.1318 million yuan as of the end of June 2025 [2][31]. Fund Performance - As of September 3, 2025, the fund's one-year cumulative net value growth rate reached 67.54%, ranking 58 out of 136 comparable funds [5]. - The fund's net value growth rates for the past three months and six months were 32.25% and 50.66%, respectively, ranking 34 out of 138 and 52 out of 138 among comparable funds [5]. Investment Strategy - The fund manager expressed optimism about the long-term potential of the innovative drug sector, focusing on companies with certainty and reasonable valuations for long-term holdings [2]. - The fund also maintains a positive outlook on the CXO/research service sector, anticipating continued demand improvement and favorable conditions for investment and financing as the Federal Reserve gradually lowers interest rates [2]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 44.55 times, significantly lower than the industry average of 120.96 times [10]. - The weighted average price-to-book (P/B) ratio was about 3.27 times, compared to the industry average of 4.07 times, and the weighted average price-to-sales (P/S) ratio was approximately 4.27 times, against an industry average of 6.52 times [10]. Growth Metrics - For the first half of 2025, the fund's weighted average revenue growth rate was 0.06%, and the weighted average net profit growth rate was 0.52% [17]. - The weighted annualized return on equity was recorded at 0.07% [17]. Fund Composition - As of June 30, 2025, the fund held a total of 4,131 investors, with a total of 58.9068 million units held [34]. - The top ten holdings included companies such as Heng Rui Pharmaceutical, Kelun-Botai Biological, and Innovent Biologics [39].
创新医疗(002173)9月4日主力资金净买入1.36亿元
Sou Hu Cai Jing· 2025-09-04 07:32
Core Viewpoint - Innovation Medical (002173) has shown a significant increase in stock price and trading volume, indicating potential investor interest despite mixed financial performance [1][2]. Financial Performance - As of the latest report, Innovation Medical's total revenue for the first half of 2025 was 402 million yuan, a year-on-year decrease of 1.6% [3]. - The company reported a net profit attributable to shareholders of -11.36 million yuan, which is a year-on-year increase of 29.12% [3]. - The second quarter of 2025 saw a single-quarter revenue of 208 million yuan, reflecting a year-on-year increase of 0.73% [3]. - The gross profit margin stands at 12.06%, significantly lower than the industry average of 35.92% [3]. Market Activity - On September 4, 2025, the stock closed at 24.99 yuan, up 5.31%, with a trading volume of 1.1823 million hands and a total transaction amount of 2.934 billion yuan [1]. - The net inflow of main funds was 136 million yuan, accounting for 4.65% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced fluctuations in fund flows, with notable net outflows from retail investors [2]. Industry Comparison - Innovation Medical's total market capitalization is 11.028 billion yuan, which is below the industry average of 20.374 billion yuan [3]. - The company ranks 34th in net profit and 40th in gross margin within the medical services industry [3]. - The price-to-earnings ratio is -485.32, indicating a loss, while the industry average is 83.81 [3].
农银创新医疗混合:2025年上半年利润9771.32万元 净值增长率17.47%
Sou Hu Cai Jing· 2025-09-04 03:36
Core Viewpoint - The AI Fund, Agricultural Bank of China Innovation Medical Mixed Fund (008293), reported a profit of 97.71 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.132 yuan. The fund's net value growth rate was 17.47%, and its scale reached 643 million yuan by the end of the first half of the year [3][33]. Fund Performance - As of September 3, the fund's unit net value was 1.085 yuan. Over the past year, the fund's return rates were 47.66% for the Agricultural Bank of China Healthcare Stock Fund and 46.06% for the Agricultural Bank of China Innovation Medical Mixed Fund [3][6]. - The fund's performance over different time frames includes a 19.88% return over the last three months, 38.88% over the last six months, and 4.89% over the last three years, ranking it 87/138, 74/138, and 72/108 among comparable funds respectively [6][28]. Market Outlook - The fund management indicated that China's economic growth is expected to stabilize around 5%, facing challenges from U.S. tariff policies and domestic structural adjustments. The management believes that the current wave of innovative drugs from China is not over and will continue to lead global technological upgrades in emerging segments [3]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 89.46 times, lower than the industry average of 120.96 times. The weighted average price-to-book (P/B) ratio was about 4.27 times, slightly above the industry average of 4.07 times [11][18]. Shareholder Composition - By June 30, 2025, the fund had 37,900 holders, with a total of 722 million shares held. Individual investors accounted for 99.68% of the holdings, while management and institutional investors held 0.07% and 0.32% respectively [36]. Top Holdings - The top ten holdings of the fund included companies such as Heng Rui Pharmaceutical, Zai Lab, and Xin Li Tai, indicating a strong focus on the pharmaceutical and biotechnology sectors [42]. Trading Activity - The fund's turnover rate for the last six months was approximately 190.99%, which is consistently lower than the industry average [39].
中银创新医疗混合A:2025年上半年利润10.55亿元 净值增长率54.08%
Sou Hu Cai Jing· 2025-09-03 15:16
Core Viewpoint - The AI Fund Zhongyin Innovation Medical Mixed A (007718) reported a profit of 1.055 billion yuan for the first half of 2025, with a weighted average profit per fund share of 0.7264 yuan, and a net asset value growth rate of 54.08% [2] Fund Performance - As of September 2, 2025, the fund's unit net value was 2.418 yuan, with a recent three-month net value growth rate of 36.41%, ranking 12 out of 138 comparable funds [5] - The fund's six-month net value growth rate was 73.73%, ranking 8 out of 138, and the one-year growth rate was 105.10%, ranking 7 out of 135 [5] - Over the past three years, the fund's net value growth rate was 83.83%, ranking 2 out of 108 [5] Fund Management Insights - The fund manager, Zheng Ning, oversees four funds, all of which have positive returns over the past year [2] - The fund's management anticipates a moderate economic slowdown in the U.S. with a potential rise in inflation, influenced by tax cuts and regulatory relaxations under uncertain Trump policies [2] Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 71.41 times, compared to the industry average of 120.96 times [10] - The weighted average price-to-book (P/B) ratio was about 5.97 times, while the industry average was 4.07 times [10] - The weighted average price-to-sales (P/S) ratio was approximately 10.65 times, against an industry average of 6.52 times [10] Growth Metrics - For the first half of 2025, the fund's weighted average revenue growth rate was 0.11%, and the weighted average net profit growth rate was 29.65% [17] - The weighted annualized return on equity was 0.08% [17] Risk and Return Metrics - As of June 30, 2025, the fund's Sharpe ratio over the past three years was 0.6073, ranking 4 out of 105 comparable funds [25] - The maximum drawdown over the past three years was 40.72%, with the largest quarterly drawdown occurring in Q1 2024 at 27% [27] Fund Composition - As of June 30, 2025, the fund had a total scale of 1.266 billion yuan, with 24,000 holders collectively owning 683 million shares [32][35] - The fund's turnover rate over the last six months was approximately 88.46%, consistently below the industry average for two years [38] - The fund's top ten holdings have consistently exceeded 60% concentration over the past two years, with major stocks including Innovent Biologics, Kelun-Biotech, and Hengrui Medicine [41]